Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular...
A new prospective study has found that initiating continuous glucose monitoring (CGM) at the point of hospital discharge is associated with significantly improved glycemic control and may halve the risk of hospital readmission for patients with type 2 diabetes. The research, published in Journal of the Endocrine Society, suggests that providing patients with real-time data...
New clinical research has identified a significant delay in skeletal maturation among children with X-linked hypophosphatemia (XLH), with male patients experiencing notably more pronounced delays than females. The study, published in Journal of The Endocrine Society, highlights a significant gap between chronological age and bone age (BA). These findings provide clinicians with more precise benchmarks...
Each month, Endocrine News presents an overview of how the Endocrine Society has been advocating for the practice and science of endocrinology, both in the U.S. and around the world. Endocrine Society Calls on Congress to Increase NIH Funding and Protect Research Because Congress is considering funding for fiscal year 2027 right now, the Endocrine Society organized a virtual Hill Day on...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Foundayo™ Weight Loss GLP-1 Pill On April 1, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet...
Endocrine Society shares concerns with The Lancet’s obesity framework Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health problems may complicate diagnosis and delay treatment, according to an Endocrine Society guideline communication published in The Journal of Clinical Endocrinology & Metabolism. “How obesity is...
Once again, Endocrine News is devoting an issue to the obesity epidemic, but this year things don’t look as dire as they have in past years. Yes, overweight and obesity is still running rampant around the world. That’s the bad news. The good news is that with the help of the spate of new pharmaceuticals,...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Novo Nordisk’s Awiqli® On March 26, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and...
Once again, Endocrine News is devoting an issue to the obesity epidemic, but this year things don’t look as dire as they have in past years. Yes, overweight and obesity is still running rampant around the world. That’s the bad news. The good news is that with the help of the spate of new pharmaceuticals,...
